We are live on
!
Find out more
VCM
Versant Capital Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
34.21%
This Fund
S&P 500
This Quarter
Est. Return
+13.52%
1 Year Est. Return
+34.21%
3 Year Est. Return
+82.39%
5 Year Est. Return
+89.4%
10 Year Est. Return
+245.39%
AUM
$1.12B
AUM Growth
+$101M
(+10%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
1.71%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
2,873
New
96
Increased
1,181
Reduced
859
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DXUV
Dimensional US Vector Equity ETF
DXUV
|
+$8.37M |
| 2 |
Dimensional Emerging Markets Core Equity 2 ETF
DFEM
|
+$7.66M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$6.75M |
| 4 |
DXIV
Dimensional International Vector Equity ETF
DXIV
|
+$4.35M |
| 5 |
Dimensional Emerging Markets Value ETF
DFEV
|
+$2.47M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 3-7 Year Treasury Bond ETF
IEI
|
+$2.11M |
| 2 |
iShares 5-10 Year Investment Grade Corporate Bond ETF
IGIB
|
+$2.02M |
| 3 |
Vanguard Total Stock Market ETF
VTI
|
+$1.88M |
| 4 |
CoreCivic
CXW
|
+$1.84M |
| 5 |
Apple
AAPL
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.06% |
| 2 | Financials | 7.05% |
| 3 | Industrials | 6.04% |
| 4 | Consumer Discretionary | 4.74% |
| 5 | Healthcare | 4.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1751
Ingles Markets
IMKTA
$1.63B
| $27.8K | ﹤0.01% |
314
+286
| +1,021% | +$25.6K |
|
1752
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
$45.8B
| $27.7K | ﹤0.01% |
53
| – | – |
|
1753
American Superconductor
AMSC
$1.48B
| $27.6K | ﹤0.01% |
665
| – | – |
|
1754
Origin Bancorp
OBK
$1.66B
| $27.6K | ﹤0.01% |
539
| – | – |
|
1755
Safety Insurance
SAFT
$1.52B
| $27.5K | ﹤0.01% |
368
+16
| +5% | +$1.17K |
|
1756
Intellia Therapeutics
NTLA
$1.5B
| $27.5K | ﹤0.01% |
1,626
-469
| -22% | -$6.56K |
|
1757
Vir Biotechnology
VIR
$1.47B
| $27.4K | ﹤0.01% |
2,690
-209
| -7% | -$1.99K |
|
1758
Axogen
AXGN
$2.1B
| $27.4K | ﹤0.01% |
593
+37
| +7% | +$1.49K |
|
1759
Farmers National Banc Corp
FMNB
$899M
| $27.4K | ﹤0.01% |
1,876
| – | – |
|
1760
Kyndryl
KD
$2.66B
| $27.3K | ﹤0.01% |
2,418
+1,233
| +104% | +$15.4K |
|
1761
Vanguard Russell 2000 ETF
VTWO
$17.3B
| $27.3K | ﹤0.01% |
225
| – | – |
|
1762
Arrowhead Research
ARWR
$12.1B
| $27.3K | ﹤0.01% |
335
+248
| +285% | +$18.3K |
|
1763
UDR
UDR
$12.9B
| $27.3K | ﹤0.01% |
684
+15
| +2% | +$555 |
|
1764
CareDx
CDNA
$1.92B
| $27.3K | ﹤0.01% |
958
| – | – |
|
1765
Evertec
EVTC
$1.83B
| $27.3K | ﹤0.01% |
981
-344
| -26% | -$9.14K |
|
1766
James River Group Holdings
JRVR
$218M
| $27.2K | ﹤0.01% |
6,179
+3,940
| +176% | +$19.4K |
|
1767
Millicom
TIGO
$15.8B
| $27.1K | ﹤0.01% |
299
+269
| +897% | +$22.7K |
|
1768
EverQuote
EVER
$886M
| $27.1K | ﹤0.01% |
1,139
-1,170
| -51% | -$21.4K |
|
1769
Chord Energy
CHRD
$7.79B
| $27.1K | ﹤0.01% |
237
+182
| +331% | +$24.7K |
|
1770
Astronics
ATRO
$3.45B
| $27.1K | ﹤0.01% |
333
-79
| -19% | -$5.39K |
|
1771
The Bancorp
TBBK
$2.79B
| $27.1K | ﹤0.01% |
432
+155
| +56% | +$8.88K |
|
1772
iShares MSCI EAFE ETF
EFA
$76.4B
| $27K | ﹤0.01% |
260
| – | – |
|
1773
Procept Biorobotics
PRCT
$950M
| $26.9K | ﹤0.01% |
1,193
+1,084
| +994% | +$27.1K |
|
1774
German American Bancorp
GABC
$1.82B
| $26.9K | ﹤0.01% |
567
| – | – |
|
|
JBTM
1775
JBT Marel
JBTM
$7.14B
| $26.8K | ﹤0.01% |
185
+11
| +6% | +$1.42K |
|
Similar funds
FLAM
AIM
MTCM
CNC
NOSC
RIM
ACG
C
Versant Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Versant Capital Management held 2,873 positions worth $1.12B, up 10% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
Versant Capital Management's Q2 2026 filing shows 96 new, 1,181 increased, 859 reduced and 128 closed positions. Its largest new stake was AstraZeneca: 7,263 shares worth $1.36M. The largest sale was iShares 3-7 Year Treasury Bond ETF, an estimated $2.11M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Financials and Industrials.
- Versant Capital Management's largest Q2 2026 buy was AstraZeneca: 7,263 shares worth $1.36M.
- Versant Capital Management added most to Dimensional US Vector Equity ETF in Q2 2026, an estimated $8.37M increase.
- Versant Capital Management's biggest Q2 2026 reduction was iShares 3-7 Year Treasury Bond ETF, cutting an estimated $2.11M.
- Versant Capital Management fully exited iShares 5-10 Year Investment Grade Corporate Bond ETF in Q2 2026, selling an estimated $2.02M.
- Versant Capital Management's ten largest holdings make up 32% of its $1.12B portfolio in Q2 2026.
- Versant Capital Management opened 96 new positions and closed 128 in Q2 2026.
- Versant Capital Management's portfolio value rose 10% quarter-over-quarter to $1.12B.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.